课题基金 / 基金详情

COMBINATION TRIAL OF DLV, ZDV AND 3TC AS INITIAL OR FOLLOWUP THERAPY (PART II)

COMBINATION TRIAL OF DLV, ZDV AND 3TC AS INITIAL OR FOLLOWUP THERAPY (PART II)
DLV、ZDV 和 3TC 作为初始或后续治疗的联合试验（第二部分）
批准号：
6281675
负责人：
PHILIP C JOHNSON
金额：
$1.36万
依托单位：
UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON
依托单位国家：
美国
项目类别：
财政年份：
1997
资助国家：
美国
项目状态：
已结题
起止时间：
1997-12-01 至 1998-11-30
来源：
https://reporter.nih.gov/project-details/6281675
关键词：
AIDS therapy HIV infections antiAIDS agent clinical research combination chemotherapy delavirdine genotype human immunodeficiency virus human subject human therapy evaluation lamivudine leukocyte count phenotype reverse transcriptase inhibitors zidovudine

项目摘要

项目成果

PHILIP C JOHNSON的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The aim of this double blind, randomized trial is to evaluate the safety and tolerance of double and triple combination therapies with and without delavirdine, a non-nucleoside reverse transcriptase inhibitor. These combinations will include DLV, zidovudine (ZDV), and lamivudine (3TC). Patients from Part I comparing ZDV with and without DLV plus new study HIV+ patients with CD4 counts of 200-500/mm3 and with 0-6 months total ZDV experience will be studied. Phenotypic and genotypic changes that emerge will also be evaluated. Interim analysis of this study showed the triple combination therapy to be better than either of the other two arms. The study will be closed by the Data Safety Monitoring Board early in 1998.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
COMPARISON OF ANTIRETROVIRAL ACTIVITY OF 3 COMBINATION REGIMENS IN HIV+ PATIENTS
AMBISOME COMPARED WITH AMPHOTERICIN B FOR HISTOPLASMOSIS IN AIDS PTS
COMPARISON OF ANTIRETROVIRAL ACTIVITY OF 3 COMBINATION REGIMENS IN HIV+ PATIENTS
AMBISOME VS AMPHOTERICIN B AND FLUCONAZOLE IN CRYPTOCOCCAL MENINGITIS IN AIDS
海外基金